Daisy F. Lazarous

TL;DR: It is concluded that intracoronary VEGF enhances the development of small coronary arteries supplying ischemic myocardium, resulting in marked augmentation of maximal collateral blood flow delivery and suggests a new therapeutic approach for the treatment of myocardial ischemia.

TL;DR: Although VEGF did not increase collateral development as administered in this study, it significantly exacerbated neointimal accumulation, which provides support for the clinical investigation of bFGF in selected patients with ischemic heart disease.

TL;DR: Exogenous administration of basic FGF enhances maximal collateral blood flow in dogs with myocardial ischemia secondary to single-vessel coronary occlusion, an effect that is likely mediated through the direct angiogenic effects of the peptide, although its acute vasodilatory effects may also play a role.

TL;DR: Systemic administration of bFGF enhanced collateral conductance in dogs with progressive single-vessel coronary occlusion, providing impetus to the concept that collateral development can be enhanced pharmacologically-specifically by bF GF-raising the possibility that such an intervention might eventually be applied clinically.

TL;DR: These data predict efficacy of intracoronary, left atrial, and pericardial bFGF for myocardial angiogenesis, and a lack of efficacy after bolus intravenous and Swan Ganz administration.